Page last updated: 2024-11-12

gibbilimbol a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gibbilimbol A: isoalted from Piper gibbilimbum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
PipergenusA plant genus of the family PIPERACEAE that includes species used for spicy and stimulating qualities.[MeSH]PiperaceaeA family of flowering plants in the order Piperales best known for the black pepper widely used in SPICES, and for KAVA and Betel used for neuroactive properties.[MeSH]

Cross-References

ID SourceID
PubMed CID10263365
CHEMBL ID503936
MeSH IDM0402891

Synonyms (4)

Synonym
4-[(e)-dec-4-enyl]phenol
gibbilimbol a
CHEMBL503936
LMJPVRXXPPOFAM-VOTSOKGWSA-N
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1278155Selectivity index, ratio of CC50 for mouse NCTC-292 cells to IC50 for Leishmania infantum amastigotes2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID401714Toxicity in Artemia salina1998Journal of natural products, Jul, Volume: 61, Issue:7
Gibbilimbols A-D, cytotoxic and antibacterial alkenylphenols from Piper gibbilimbum.
AID1278152Selectivity index, ratio of CC50 for mouse NCTC-292 cells to IC50 for Trypanosoma cruzi Y trypomastigotes2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID401716Antibacterial activity against Staphylococcus epidermidis at 60 ug/disk by paper disk diffusion technique1998Journal of natural products, Jul, Volume: 61, Issue:7
Gibbilimbols A-D, cytotoxic and antibacterial alkenylphenols from Piper gibbilimbum.
AID401717Antibacterial activity against Bacillus cereus at 60 ug/disk by paper disk diffusion technique1998Journal of natural products, Jul, Volume: 61, Issue:7
Gibbilimbols A-D, cytotoxic and antibacterial alkenylphenols from Piper gibbilimbum.
AID401719Antibacterial activity against Staphylococcus epidermidis after 24 hrs by broth microdilution method1998Journal of natural products, Jul, Volume: 61, Issue:7
Gibbilimbols A-D, cytotoxic and antibacterial alkenylphenols from Piper gibbilimbum.
AID401718Antibacterial activity against Pseudomonas aeruginosa at 60 ug/disk by paper disk diffusion technique1998Journal of natural products, Jul, Volume: 61, Issue:7
Gibbilimbols A-D, cytotoxic and antibacterial alkenylphenols from Piper gibbilimbum.
AID1278151Cytotoxicity against mouse NCTC-929 cells assessed as cell viability after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID1278148Antiparasitic activity against amastigote stage of Trypanosoma cruzi Y2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID1278149Antiparasitic activity against promastigote stage of Leishmania infantum assessed as parasite viability after 24 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID1278150Antiparasitic activity against amastigote stage of Leishmania infantum infected in BALB/c mouse peritoneal macrophages assessed as reduction of parasite burden after 120 hrs by Giemsa staining-based light microscopic analysis2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID1278147Antiparasitic activity against trypomastigote stage of Trypanosoma cruzi Y assessed as parasite viability after 24 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.
AID401720Antibacterial activity against Bacillus cereus after 24 hrs by broth microdilution method1998Journal of natural products, Jul, Volume: 61, Issue:7
Gibbilimbols A-D, cytotoxic and antibacterial alkenylphenols from Piper gibbilimbum.
AID401715Cytotoxicity against human KB cells1998Journal of natural products, Jul, Volume: 61, Issue:7
Gibbilimbols A-D, cytotoxic and antibacterial alkenylphenols from Piper gibbilimbum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]